We are faced with a serious problem, one requiring the full faith and credit of the free market. We need to unleash resources and creativity. That’s what markets do best, right?
The problem is drug-resistant bacteria and diseases that cannot be cured with existing strains of antibiotics. Yet market incentives are perverse. The marketplace is just as often our enemy as our friend.
This is from an article by Jerome Groopman in the New Yorker, Superbugs, August 11/18 issue:
In the past, large pharmaceutical companies were the primary sources of antibiotic research. But many of these companies have abandoned the field. “Eli Lilly and Company developed the first cephalosporins,” Moellering told me, referring to familiar drugs like Keflex. “They developed a huge number of important anti-microbial agents. They had incredible chemistry and incredible research facilities, and, unfortunately, they have completely pulled out of it now. After Squibb merged with Bristol-Myers, they closed their antibacterial program,” he said, as did Abbott, which developed key agents in the past treatment of gram-negative bacteria. A recent assessment of progress in the field, from U.C.L.A., concluded, “FDA approval of new antibacterial agents decreased by 56 per cent over the past 20 years (1998-2002 vs. 1983-1987),” noting that, in the researchers’ projection of future development only six of the five hundred and six drugs currently being developed were new antibacterial agents. Drug companies are looking for blockbuster therapies that must be taken daily for decades, drugs like Lipitor, for high cholesterol, or Zyprexa, for psychiatric disorders, used by millions of people and generating many billions of dollars each year. Antibiotics are used to treat infections, and are therefore prescribed only for days or weeks. (The exception is the use of antibiotics in livestock, which is both a profit-driver and a potential cause of antibiotic resistance.)
If there is a solution to this problem, it will come from the college campuses and the National Institute of Health – government sources. The market is not helping – in fact – is structurally unable to help. This phenomenon is known as “market failure” – the public is disserved by the profit motive. In such situations, government has to intervene to provide for the greater good.
It’s interesting – I realized as I wrote those words that in the past in my exchanges with Dave Budge (a libertarian conservative Republican who at any given time denies affiliation to any of those three schools), he claimed not to grasp the concepts of “market failure” and “greater good”. Ayn Rand herself did not believe in individuals sacrificing to a greater good – that is, she did not think there was any point in people serving anything but their own self-interest. Perhaps libertarianism, a sideshow that has much greater currency in leadership circles than among the general population, is a failed philosophy.
Superbugs are a common problem affecting all of us. Those institutions that profit from the public’s need for drugs have an obligation to step in and help us solve the problem. But they’re not – they’re busy doing the self-interest thing. Rand would be proud.

